TY - JOUR
T1 - Neoantigens in Chronic Obstructive Pulmonary Disease and Lung Cancer
T2 - A Point of View
AU - Zeneyedpour, Lona
AU - Dekker, Lennard J.M.
AU - van Sten-van`t Hoff, Jenny J.M.
AU - Burgers, Peter C.
AU - ten Hacken, Nick H.T.
AU - Luider, Theo M.
N1 - Publisher Copyright:
© 2019 The Authors. Proteomics – Clinical Application published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
PY - 2019/3
Y1 - 2019/3
N2 - The goal of this manuscript is to explore the role of clinical proteomics for detecting mutations in chronic obstructive pulmonary disease (COPD) and lung cancer by mass spectrometry-based technology. COPD and lung cancer caused by smoke inhalation are most likely linked by challenging the immune system via partly shared pathways. Genome-wide association studies have identified several single nucleotide polymorphisms which predispose an increased susceptibility to COPD and lung cancer. In lung cancer, this leads to coding mutations in the affected tissues, development of neoantigens, and different functionality and abundance of proteins in specific pathways. If a similar reasoning can also be applied in COPD will be discussed. The technology of mass spectrometry has developed into an advanced technology for proteome research detecting mutated peptides or proteins and finding relevant molecular mechanisms that will enable predicting the response to immunotherapy in COPD and lung cancer patients.
AB - The goal of this manuscript is to explore the role of clinical proteomics for detecting mutations in chronic obstructive pulmonary disease (COPD) and lung cancer by mass spectrometry-based technology. COPD and lung cancer caused by smoke inhalation are most likely linked by challenging the immune system via partly shared pathways. Genome-wide association studies have identified several single nucleotide polymorphisms which predispose an increased susceptibility to COPD and lung cancer. In lung cancer, this leads to coding mutations in the affected tissues, development of neoantigens, and different functionality and abundance of proteins in specific pathways. If a similar reasoning can also be applied in COPD will be discussed. The technology of mass spectrometry has developed into an advanced technology for proteome research detecting mutated peptides or proteins and finding relevant molecular mechanisms that will enable predicting the response to immunotherapy in COPD and lung cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=85061442031&partnerID=8YFLogxK
U2 - 10.1002/prca.201800093
DO - 10.1002/prca.201800093
M3 - Article
C2 - 30706659
AN - SCOPUS:85061442031
SN - 1862-8346
VL - 13
JO - Proteomics - Clinical Applications
JF - Proteomics - Clinical Applications
IS - 2
M1 - 1800093
ER -
